| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8794983 | Ophthalmology Retina | 2017 | 8 Pages |
Abstract
Although 17% of study eyes without GA present at baseline receiving ranibizumab developed new GA, the role of ranibizumab in the development of GA is unclear. Further prospective longitudinal studies are required to determine the eyes most at risk of developing GA in the setting of anti-vascular endothelial growth factor treatment.
Keywords
CNVnAMDCATTAREDSFAFPRNICGNIHRPEAMDRAPChoroidal neovascularizationgeographic atrophyfluorescein angiographyretinal pigment epitheliumOctIndocyanine greenAge-Related Eye Disease StudyOptical coherence tomographyretinal angiomatous proliferationVisual acuityneovascular age-related macular degenerationage-related macular degenerationpro re nataVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)fundus autofluorescenceNational Institutes of Health
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Alisa T. MD, Naima MD, Jane S. MD, Elvira MA, Jesia MD, Catherine B. MD, David DO, Catherine A. MD, PhD, Henry E. MD, Wai T. MD, PhD, Emily Y. MD,